News Release

Printer Friendly Version View printer-friendly version
<< Back
Misonix Announces New Distribution Agreement for Algeria

FARMINGDALE, N.Y., Nov. 15, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, has entered into a new, two year, exclusive distribution agreement with SARL EXCELLENCE SANTE (SES) of Algiers, Algeria for the distribution of the SonaStar® Ultrasonic Surgical Aspirator and the BoneScalpel™ Ultrasonic Bone Cutter.  The agreement provides SES with the rights to sell throughout Algeria.  Included in the agreement are annual minimum purchase requirements.  Initial product training is complete and open market sales are underway.

SES is a respected distributor of state-of-the-art medical devices and has successfully launched multiple new products into Algeria, including capital equipment-based surgical systems, and is well known for their commitment to service and physician training, particularly in the fields of Spine Surgery, Orthopedic Surgery and Neurosurgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels.  In addition, OsteoSculpt™ bone sculpting technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.

"Misonix is very pleased to have SES become our third distributor for emerging markets on the African continent.  Their reputation as a quality distributor of advanced medical equipment has been established," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  "Their commitment to clinical education and service matches Misonix's own values in these areas.  We are particularly pleased that they will be selling two of our key products throughout Algeria."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
212-245-4577
Kevin@cameronassoc.com

SOURCE Misonix, Inc.

Misonix Contact: Richard Zaremba, +1-631-694-9555, invest@misonix.com